Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
April 13 2022 - 8:30AM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced
that ART27.13, a peripherally selective G-Protein Coupled Receptor
(GPCR) full agonist currently in clinical development for
cancer-related anorexia, shows promising pre-clinical results in
protecting human muscle cells from cancer-induced muscle
degeneration (cachexia) via a CB2 mediated mechanism of action.
“These are very encouraging data for two important reasons,”
said Richard Porter, Ph.D., of the School of Biochemistry &
Immunology at Trinity College Dublin, Ireland. “For the first time,
we have evidence that ART27.13 targets a second mechanism of
action, the cannabinoid receptor CB2, with these positive
pre-clinical results. Furthermore, this mechanism of action extends
the potential benefit of ART27.13 to treating cachexia in addition
to appetite loss and body weight regulation via CB1 mediated
activity.”
“These exciting early results demonstrate that ART27.13 is
capable of reducing negative effects of chemicals produced by
multiple cancers on human muscle fibers,” added Saoirse O’Sullivan,
Ph.D., Vice President Translational Science, Artelo Biosciences.
“We look forward to seeing how these results may translate into the
ongoing CAReS study currently in the final stages of enrolling
cohort 3 at six clinical trial sites in the United Kingdom and
Ireland.”
About Cancer-Related CachexiaCachexia is a
multi-organ, and often irreversible, muscle-wasting syndrome
associated with cancer and other serious chronic illnesses. It
affects up to 80% of patients with advanced cancer and causes
reduced tolerance to cancer therapies, quality of life, and
survival rates. Cachexia is an unmet medical need in oncology for
which there is no approved therapy.
About ART27.13ART27.13 is a once-a-day, orally
administered, highly potent, peripherally restricted synthetic,
dual GPCR agonist believed to target the cannabinoid receptors
CB1/CB2, which has the potential to increase appetite, food intake
and reduce muscle wasting. Originally developed by AstraZeneca plc,
ART27.13 has been studied in five Phase 1 clinical studies
including over 200 subjects. In the multiple ascending dose study
in 50 patients with back pain who were otherwise healthy, a
dose-dependent increase in body weight was observed. Importantly,
the changes in body weight apparently were not associated with
fluid retention and the distribution of the drug enables systemic
metabolic effects while minimizing central nervous system mediated
toxicity. Artelo is advancing the development of ART27.13 as a
supportive care therapy for cancer patients suffering from anorexia
and weight loss in the Cancer Appetite Recovery Study (CAReS). The
current annual global market for the treatment of cancer-related
anorexia is estimated to be valued in excess of $2 billion. More
information is available
at https://artelobio.com/pipeline/art27-13/
About Artelo Biosciences Artelo Biosciences,
Inc. is a San Diego-based biopharmaceutical company dedicated
to the development and commercialization of proprietary
therapeutics targeting endogenous signaling pathways including the
endocannabinoid system. Artelo is rapidly advancing a portfolio of
broadly applicable product candidates designed to address
significant unmet needs in multiple diseases and conditions,
including anorexia, cancer, PTSD, pain, and inflammation. Led by
proven biopharmaceutical executives collaborating with highly
respected researchers and technology experts, the company applies
leading edge scientific, regulatory, and commercial discipline to
develop high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024